Current Report Filing (8-k)
December 09 2022 - 04:01PM
Edgar (US Regulatory)
0001711754 false 0001711754 2022-12-08
2022-12-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported):
December 8, 2022
|
INMUNE BIO INC. |
| (Exact
name of registrant as specified in charter) |
|
Nevada |
|
001-38793 |
|
47-5205835 |
| (State
or other jurisdiction |
|
(Commission
File Number) |
|
(IRS
Employer |
| of
incorporation) |
|
|
|
Identification
No.) |
225 NE Mizner Boulevard,
Suite 640,
Boca Raton,
FL
33432
(Address of Principal Executive Offices) (Zip Code)
(858)964-3720
(Registrant’s Telephone Number, Including Area Code)
Not
Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction
A.2. below):
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mart if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock, par value $0.001 per share |
|
INMB |
|
The
NASDAQ Stock Market LLC |
Item 8.01. Other Events.
On December 8, 2022, INmune Bio Inc. (the “Company”) issued a press
release announcing that will
present data from UK patients with MDS or AML treated with INKmune™
at the annual American Society for Hematology (ASH) Conference held
in New Orleans December 10th –
13th. A copy of this press release is attached
herewith as Exhibit 99.1.
Additionally, the Company is filing as Exhibit 99.2 to this Current
Report on Form 8-K a slide deck that the Company intends to use in
a presentation.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Date:
December 9, 2022 |
INMUNE BIO
INC. |
| |
|
| |
By: |
/s/
David Moss |
| |
|
David Moss |
| |
|
Chief Financial
Officer |
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From May 2023 to Jun 2023
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jun 2022 to Jun 2023
